2016
DOI: 10.21037/tgh.2016.01.06
|View full text |Cite
|
Sign up to set email alerts
|

Is a “wait-and-see” policy the best for small gastric gastrointestinal stromal tumor (GIST)?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 16 publications
0
2
0
Order By: Relevance
“…Next, we sought to further investigate the ability of crExos GPC1 to diagnose PDAC. Several authors have asked for the results from Melo et al [ 12 ] to be confirmed in an independent series of patients [ 16 , 17 ]. These additional data would help to validate crExos GPC1 as a blood-based biomarker for the detection of PDAC [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…Next, we sought to further investigate the ability of crExos GPC1 to diagnose PDAC. Several authors have asked for the results from Melo et al [ 12 ] to be confirmed in an independent series of patients [ 16 , 17 ]. These additional data would help to validate crExos GPC1 as a blood-based biomarker for the detection of PDAC [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…In our study, there were 17 intermediate/high-risk patients (6.2%). Thus, screening out patients with intermediate/high-risk cases of small gGIST is still a clinical challenge (10,21).…”
Section: Discussionmentioning
confidence: 99%